Abstracts tagged "rheumatoid arthritis (RA) and tumor necrosis factor (TNF)"

Abstract Number: 1008 • 2018 ACR/ARHP Annual Meeting
Presence of a Specific Defect in M2 Polarization of Blood Monocytes from Patients with Rheumatoid Arthritis, Associated with Increased microRNA-155
Audrey Paoletti¹, Julien Rohmer², Juliette Pascaud³, Bineta Oumouly¹, Elodie Rivière³, Samuel Bitoun⁴, Gaetane Nocturne⁵ and Xavier Mariette⁶, ¹U1184 IMVA, INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, le kremlin bicetre, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Internal medicine, France, Paris, France, ³Immunology of viral Infections and Autoimmune Diseases, IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre & Fontenay aux Roses, France, ⁴INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, le kremlin bicetre, France, ⁵INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicêtre, France, ⁶Rheumatology department, Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique- Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, Paris, France
Background/Purpose: Macrophages contribute in situ to the RA pathogenesis. Two distinct states of polarization for macrophages have been recognized: the classically activated macrophage phenotype (M1),…
Abstract Number: 1052 • 2018 ACR/ARHP Annual Meeting
Detection of Precursors of RANK- Osteoclast-like Cells (Olcs) in Peripheral Blood and Olcs in Bone Tissue from Rheumatoid Arthritis Patients
Kazuhiro Yokota¹, Shinya Tanaka², Miyoko Sekikawa², Yoshimi Aizaki¹, Kojiro Sato¹, Hiromi Oda² and Toshihide Mimura¹, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Department of Orthopaedic Surgery, Saitama Medical University, Saitama, Japan
Background/Purpose: Proinflammatory cytokines play an important role in bone destruction in rheumatoid arthritis (RA), as inferred by the efficacy of biologics. Previously, we reported that…
Abstract Number: 1192 • 2018 ACR/ARHP Annual Meeting
The Impact of Participation in an Adalimumab (Humira) Patient Support Program on the Onset and Management of Disease Flares
Filip van Den Bosch¹, Siegfried Wassenberg², Boulos Haraoui³, Patrick Zueger⁴, Meijing Wu⁴, Ivan Lagunes Galindo⁴ and Andrew Ostor⁵, ¹Ghent University Hospital, Ghent, Belgium, ²Rheumazentrum Ratingen, Ratingen, Germany, ³Université de Montréal, Montreal, QC, Canada, ⁴AbbVie Inc., North Chicago, IL, ⁵Cabrini Medical Center, Melbourne, Australia
Background/Purpose: The AbbVie patient (pt) support program (PSP) is offered to pts prescribed adalimumab for RA and other indications. The purpose of this analysis was…
Abstract Number: 1522 • 2018 ACR/ARHP Annual Meeting
Time Dependent Effect of Biologic Therapy on Overall Survival in Patients with Rheumatoid Arthritis and Cancer
Xerxes Pundole¹, Natalia Zamora², Harish Siddhanamatha³, Jean Tayar⁴, Cheuk Hong Leung⁵, Heather Lin⁶ and Maria Suarez-Almazor⁷, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ³The University of Texas Health Science Center, School of Biomedical Informatics, Houston, TX, USA, Houston, TX, ⁴Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, ⁵Department of Biostatistics, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁶Biostatistics, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁷Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) are commonly used in the treatment of rheumatoid arthritis (RA). But the use of bDMARDs in patients with RA…
Abstract Number: 1528 • 2018 ACR/ARHP Annual Meeting
Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)
Gerd R. Burmester¹, Owen Hagino², Qunming Dong³, Marina Stanislav⁴, Antonio Gomez-Centeno⁵, Carlo Selmi⁶, Tom W.J. Huizinga⁷, Erin Mangan⁸, Cem Gabay⁹ and Mark C. Genovese¹⁰, ¹Charité – University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ²Sanofi Genzyme, Bridgewater, NJ, ³Sanofi, Bridgewater, NJ, ⁴Scientific Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, Russian Federation, ⁵Corporació Sanitària Parc Taulí, Barcelona, Spain, ⁶Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁹University Hospitals of Geneva, Geneva, Switzerland, ¹⁰Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Anemia (WHO criteria: Hemoglobin [Hb] levels <12.0 g/dL [females] or <13.0 g/dL [males]) is a common finding associated with increased joint inflammation in patients…
Abstract Number: 2188 • 2018 ACR/ARHP Annual Meeting
Regional Analysis of Impact of Participation in a Patient Support Program on Clinical Outcomes Among Patients with Rheumatoid Arthritis Receiving Adalimumab (Humira)
Filip van Den Bosch¹, Andrew Ostor², Patrick Zueger³, Meijing Wu³, Ivan Lagunes Galindo³ and Siegfried Wassenberg⁴, ¹Ghent University Hospital, Ghent, Belgium, ²Cabrini Medical Center, Melbourne, Australia, ³AbbVie Inc., North Chicago, IL, ⁴Rheumazentrum Ratingen, Ratingen, Germany
Background/Purpose: Patients (pts) receiving adalimumab for RA or other indications are offered participation in the AbbVie pt support program (PSP). This analysis assessed clinical outcomes…
Abstract Number: 2331 • 2018 ACR/ARHP Annual Meeting
Obesity Might Positively Affect TNF Mediated Bone Metabolism in RA Patients
Mie Jin Lim¹, Won Park², Seong Ryul Kwon³, Kyong-Hee Jung⁴ and Seung Yun Lee³, ¹Division of Rheumatology, Departments of Internal Medicine, Inha University Hospital, Incheon, Korea, Republic of (South), ²Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, Korea, Republic of (South), ⁴Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South)
Background/Purpose: In this study, we tried to find out the effect of obesity on bone metabolism after one year of anti-TNF agent use. Methods: Thirty-two…
Abstract Number: 2595 • 2018 ACR/ARHP Annual Meeting
Golimumab Improves Socio- and Health Economic Parameters in Patients with RA, Psa and As: Real World-Data from a Non-Interventional Clinical Study in Germany
Klaus Krüger¹, Gerd R. Burmester², Siegfried Wassenberg³, Valeria Biermann⁴ and Matthias H. Thomas⁵, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ³Rheumazentrum Ratingen, Ratingen, Germany, ⁴Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg, Nürnberg, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and safety in various clinical trials. Data from socio- and health economic parameters and costs in daily clinical…
Abstract Number: 2820 • 2018 ACR/ARHP Annual Meeting
Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial
Yoshiya Tanaka¹, Koji Oba^2,3, Takao Koike^4,5, Nobuyuki Miyasaka⁶, Tsuneyo Mimori⁷, Tsutomu Takeuchi⁸, Shintaro Hirata⁹, Eiichi Tanaka¹⁰, Hidekata Yasuoka¹¹, Yuko Kaneko⁸, Kosaku Murakami⁷, Tomohiro Koga¹², Kazuhisa Nakano¹³, Koichi Amano¹⁴, Kazuyasu Ushio¹⁵, Tatsuya Atsumi¹⁶, Masayuki Inoo¹⁷, Kazuhiro Hatta¹⁸, Shinichi Mizuki¹⁹, Shohei Nagaoka²⁰, Shinichiro Tsunoda²¹, Hiroaki Dobashi²², Nao Horie³ and Norihiro Sato³, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan, ³Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan, ⁴Hokkaido Medical Center for Rheumatic Diseases, Sapporo, Japan, ⁵NTT Sapporo Medical Center, Sapporo, Japan, ⁶Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ⁷Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁹Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ¹⁰Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, tokyo, Japan, ¹²Center for Bioinformatics and Molecular Medicine, Nagasaki University, Graduate School of Biomedical Sciences, Nagasaki, Japan, ¹³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁴Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ¹⁵Ushio Clinic, Osaka, Japan, ¹⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ¹⁷Utazu hospital, Utatsu-cho, Japan, ¹⁸Department of General Medicine, Tenri Hospital, Tenri, Japan, ¹⁹Center for Rheumatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Japan, ²⁰Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, ²¹Division of Rheumatology Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²²Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Kagawa University, Miki-cho, Japan
Background/Purpose: Infliximab (IFX), a TNF inhibitor, is one of the most widely used biological disease-modifying antirheumatic drugs. Recent studies indicated that baseline levels of serum…
Abstract Number: 2485 • 2017 ACR/ARHP Annual Meeting
Outcomes of Switching from TNF Inhibitors to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
Hiroki Wakabayashi¹, Hitoshi Inada², Yosuke Nishioka³, Masahiro Hasegawa^1,4, Kusuki Nishioka⁵ and Akihiro Sudo⁶, ¹Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, ²Orthopaedic Surgery, Suzuka General Hospital, Suzuka, Japan, ³Clinical Research Institute for Rheumatic Disease, Shima, Japan, ⁴Mie University Graduate School of Medicine, Tsu, Japan, ⁵Tokyo Medical University, Shinjuku, Japan, ⁶Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan
Background/Purpose: Tumor necrosis factor alpha (TNFα) inhibitors have been used to treat rheumatoid arthritis (RA) for >10 years. The outcomes has revolutionized the treatment goal…
Abstract Number: 75 • 2017 ACR/ARHP Annual Meeting
Factors Associated with TNF Receptor 2 Levels Above the Measurable Range in Rheumatoid Arthritis
Michelle Frits¹, Gary Bradwin², Nancy A. Shadick¹, Christine Iannaccone³, Michael Weinblatt¹, Nader Rifai² and Katherine P. Liao⁴, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Laboratory Medicine, Childrens Hospital Boston, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Tumor necrosis factor-alpha (TNFa) is involved in the pathogenesis of RA and is increasingly being studied as a biomarker of cardiovascular disease (CVD). While…
Abstract Number: 2711 • 2017 ACR/ARHP Annual Meeting
Mucosal-Associated Invariant T Cells Are an Important Source of TNF in Rheumatoid Arthritis
Diahann Jansen¹, Elizabeth Klinken¹, Hendrik Nel¹, Soi Cheng Law¹, Hester Koppejan², Marjolijn Hameetman³, Ligong Liu⁴, Alexandra Corbett⁵, Sidonia Eckle⁵, David Fairlie⁴, Rene E.M. Toes⁶, Floris van Gaalen⁷, Jamie Rossjohn^8,9,10, James McCluskey⁵ and Ranjeny Thomas¹, ¹The University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, Australia, ²Department of Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia, ⁵Department of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Australia, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Australia, ⁹Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, ¹⁰Infection and Immunity Program, Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia
Background/Purpose: CD8+ T cells have been described to comprise up to 40% of the rheumatoid arthritis (RA) synovial T cell compartment but their pathogenic function…
Abstract Number: 139 • 2017 ACR/ARHP Annual Meeting
No Effect of Tumor Necrosis Factor-a Inhibitors on Renal Function in Patients with Rheumatoid Arthritis from Kobio Registry from 2012 to 2016
Seong-Kyu Kim¹, Jung-Yoon Choe², Sung-Hoon Park³ and Hwajeong Lee², ¹Rheumatology, Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South), ²Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South), ³Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South)
Background/Purpose: Renal disease is prevalent in patients with rheumatoid arthritis (RA), although the precise prevalence of RA has not been determined. Increased mortality in patients…
Abstract Number: 2864 • 2017 ACR/ARHP Annual Meeting
Anti-Acetylated Peptide Antibodies Positive Rheumatoid Arthritis Patients Show a More Favorable Response to Tumor-Necrosis-Factor Inhibitor Treatment and Better Disease Activity Control over Time
Paul Studenic¹, Stephan Blüml¹, Holger Bang², Daniela Sieghart¹, Daniel Aletaha¹, Helmuth Haslacher³, Josef S. Smolen^1,4 and Günter Steiner¹, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Medical University Vienna, Department of Laboratory Medicine, Vienna, Austria, ⁴Department of Internal Medicine, Hietzing Hospital, Vienna, Austria
Background/Purpose: Anti-acetylated-peptide antibodies (AAPA) have been found in rheumatoid arthritis (RA) patients and may be additional markers for diagnosis, particularly in rheumatoid factor (RF)/ anti-citrullinated…
Abstract Number: 515 • 2017 ACR/ARHP Annual Meeting
Leukopenia and Tumor Necrosis Factor Alpha Inhibitor Therapy
Wenlu Xiong¹, Rochella A. Ostrowski², William Adams³ and Rodney Tehrani⁴, ¹Rheumatology, Vanderbilt University Medical Center, Nashville, TN, ²Rheumatology, Loyola University Medical Center, Maywood, IL, ³Clinical Research Office, Loyola University Medical Center, Maywood, IL, ⁴Rheumatology & Immunology, Loyola University Medical Center, Maywood, IL
- Background/Purpose: Tumor necrosis factor (TNF) alpha, a key proinflammatory cytokine in rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), has been a major target in…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].